Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer: Case reports and review of the literature

Lene Thorsen, Hege S Haugnes, Sophie D Fosså, Marianne Brydøy, Torgrim Tandstad, Torbjørn Wisløff, Gunhild M Gjerset, Elisabeth Edvardsen, Karl-Otto Larsen, Per Morten Sandset, Carola E Henriksson, Truls Raastad, Helene F S Negaard, Lene Thorsen, Hege S Haugnes, Sophie D Fosså, Marianne Brydøy, Torgrim Tandstad, Torbjørn Wisløff, Gunhild M Gjerset, Elisabeth Edvardsen, Karl-Otto Larsen, Per Morten Sandset, Carola E Henriksson, Truls Raastad, Helene F S Negaard

Abstract

The randomized "Testicular cancer and Aerobic and Strength Training trial" (TAST-trial) aimed to evaluate the effect of high-intensity interval training (HIIT) on cardiorespiratory fitness during cisplatin-based chemotherapy (CBCT) for testicular cancer (TC). Here, we report on an unexpected high number of thromboembolic (TE) events among patients randomized to the intervention arm, and on a review of the literature on TE events in TC patients undergoing CBCT. Patients aged 18 to 60 years with a diagnosis of metastatic germ cell TC, planned for 3 to 4 CBCT cycles, were randomized to a 9 to 12 weeks exercise intervention, or to a single lifestyle counseling session. The exercise intervention included two weekly HIIT sessions, each with 2 to 4 intervals of 2 to 4 minutes at 85% to 95% of peak heart rate. The study was prematurely discontinued after inclusion of 19 of the planned 94 patients, with nine patients randomized to the intervention arm and 10 to the control arm. Three patients in the intervention arm developed TE complications; two with pulmonary embolism and one with myocardial infarction. All three patients had clinical stage IIA TC. No TE complications were observed among patients in the control arm. Our observations indicate that high-intensity aerobic training during CBCT might increase the risk of TE events in TC patients, leading to premature closure of the TAST-trial.

Trial registration: ClinicalTrials.gov NCT02577172.

Keywords: cisplatin-based chemotherapy; high-intensity training; testicular cancer; thromboembolic events.

© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

References

REFERENCES

    1. Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv. 2010;4:87-100.
    1. Loughney L, West MA, Kemp GJ, Grocott MPW, Jack S. Exercise intervention in people with cancer undergoing neoadjuvant cancer treatment and surgery: a systematic review. Eur J Surg Oncol. 2016;42:28-38.
    1. Segal R, Zwaal C, Green E, et al. Exercise for people with cancer: a systematic review. Curr Oncol. 2017;24:e290-e315.
    1. Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer JClin. 2012;62:243-274.
    1. Segal R, Zwaal C, Green E, et al. Exercise for people with cancer: a clinical practice guideline. Curr Oncol. 2017;24:40-46.
    1. Campbell KL, Winters-Stone KM, Wiskemann J, et al. Exercise guidelines for cancer survivors: consensus Statement from international multidisciplinary roundtable. Med Sci Sports Exerc. 2019;51:2375-2390.
    1. Loughney LA, West MA, Kemp GJ, Grocott MP, Jack S. Exercise interventions for people undergoing multimodal cancer treatment that includes surgery. Cochrane Database Syst Rev. 2018;(12):CD012280.
    1. Adamsen L, Quist M, Andersen C, et al. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. BMJ. 2009;339:b3410.
    1. Andersen C, Rorth M, Ejlertsen B, et al. The effects of a six-week supervised multimodal exercise intervention during chemotherapy on cancer-related fatigue. Eur J Oncol Nurs. 2013;17:331-339.
    1. Hornsby WE, Douglas PS, West MJ, et al. Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial. Acta Oncol. 2014;53:65-74.
    1. van Waart H, Stuiver MM, van Harten WH, et al. Effect of low-intensity physical activity and moderate- to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial. J Clin Oncol. 2015;33:1918-1927.
    1. Mijwel S, Backman M, Bolam KA, et al. Adding high-intensity interval training to conventional training modalities: optimizing health-related outcomes during chemotherapy for breast cancer: the OptiTrain randomized controlled trial. Breast Cancer Res Treat. 2017;168:79-93.
    1. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA. 2008;299:672-684.
    1. Sprauten M, Haugnes HS, Brydoy M, et al. Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors. Ann Oncol. 2015;26:2133-2140.
    1. Haugnes HS, Bosl GJ, Boer H, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol. 2012;30:3752-3763.
    1. Christensen JF, Andersen JL, Adamsen L, et al. Progressive resistance training and cancer testis (PROTRACT)-efficacy of resistance training on muscle function, morphology and inflammatory profile in testicular cancer patients undergoing chemotherapy: design of a randomized controlled trial. BMC Cancer. 2011;11:326.
    1. Borg G. Perceived Exertion and Pain Scales. Champaign, IL: Human Kinetics; 1998.
    1. Thorsen L, Kirkegaard C, Loge JH, et al. Feasibility of a physical activity intervention during and shortly after chemotherpay for testicual cancer. BMC Res Notes. 2017;10:214.
    1. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15:594-603.
    1. Lubberts S, Boer H, Altena R, et al. Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy. Eur J Cancer. 2016;63:180-188.
    1. Nuver J, Smit AJ, van der Meer J, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol. 2005;23:9130-9137.
    1. Cantwell BM, Mannix KA, Roberts JT, Ghani SE, Harris AL. Thromboembolic events during combination chemotherapy for germ cell-malignancy. Lancet. 1988;2:1086-1087.
    1. Paffenholz P, Grein K, Heidegger I, et al. Predictors of thrombosis in testicular cancer during platinum-based chemotherapy. World J Urol. 2019;37:1907-1916.
    1. Heidegger I, Porres D, Veek N, Heidenreich A, Pfister D. Predictive factors for developing venous thrombosis during Cisplatin-based chemotherapy in testicular cancer. Urol Int. 2017;99:104-109.
    1. Bezan A, Posch F, Ploner F, et al. Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. PLoS One. 2017;12:e0176283.
    1. Gonzalez-Billalabeitia E, Castellano D, Sobrevilla N, et al. Prognostic significance of venous thromboembolic events in disseminated germ cell cancer patients. J Natl Cancer Inst. 2017;109:djw265.
    1. Gizzi M, Oberic L, Massard C, et al. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. Eur J Cancer. 2016;69:151-157.
    1. Solari L, Kronig M, Ihorst G, et al. High rates of thromboembolic events in patients with germ cell cancer undergoing cisplatin-based polychemotherapy. Urol Int. 2016;96:399-405.
    1. Srikanthan A, Tran B, Beausoleil M, et al. Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. J Clin Oncol. 2015;33:582-587.
    1. Honecker F, Koychev D, Luhmann AD, et al. Venous thromboembolic events in germ cell cancer patients undergoing platinum-based chemotherapy. Onkologie. 2013;36:663-668.
    1. de Haas EC, Zwart N, Meijer C, et al. Association of PAI-1 gene polymorphism with survival and chemotherapy-related vascular toxicity in testicular cancer. Cancer. 2010;116:5628-5636.
    1. Piketty AC, Flechon A, Laplanche A, et al. The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer. 2005;93:909-914.
    1. Weijl NI, Rutten MF, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000;18:2169-2178.
    1. Dieckmann KP, Gerl A, Witt J, Hartmann JT, German Testicular Cancer Study Group, et al. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol. 2010;21:1607-1611.
    1. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902-4907.
    1. Barni S, Labianca R, Agnelli G, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med. 2011;9:179.
    1. Bertina RM. The role of procoagulants and anticoagulants in the development of venous thromboembolism. Thromb Res. 2009;123 Suppl 4:S41-S45.
    1. Jackson SP. Arterial thrombosis-insidious, unpredictable and deadly. Nat Med. 2011;17:1423-1436.
    1. Dieckmann KP, Struss WJ, Budde U. Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour. Anticancer Res. 2011;31:4501-4505.
    1. Nuver J, de Haas EC, van Zweeden M, Gietema JA, Meijer C. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep. 2010;23:247-253.
    1. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA. 1989;86:2839-2843.
    1. Mackman N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis. 2006;36:104-107.
    1. El-Sayed MS, El-Sayed Ali Z, Ahmadizad S. Exercise and training effects on blood haemostasis in health and disease: an update. Sports Med. 2004;34:181-200.
    1. Wang JS. Intense exercise increases shear-induced platelet aggregation in men through enhancement of von Willbrand factor binding, glycoprotein IIb/IIIa activation, and P-selectin expression on platelets. Eur J Appl Physiol. 2004;91:741-747.
    1. Mockel M, Ulrich NV, Heller G Jr, et al. Platelet activation through triathlon competition in ultra-endurance trained athletes: impact of thrombin and plasmin generation and catecholamine release. Int J Sports Med. 2001;22:337-343.
    1. Li N, He S, Blomback M, Hjemdahl P. Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaparin. Arterioscler Thromb Vasc Biol. 2007;27:407-413.
    1. Andrew M, Carter C, O'Brodovich H, Heigenhauser G. Increases in factor VIII complex and fibrinolytic activity are dependent on exercise intensity. J Appl Physiol (1985). 1986;60:1917-1922.
    1. Hansen JB, Wilsgard L, Olsen JO, Osterud B. Formation and persistence of procoagulant and fibrinolytic activities in circulation after strenuous physical exercise. Thromb Haemost. 1990;64:385-389.
    1. Ahmadizad S, Nouri-Habashi A, Rahmani H, et al. Platelet activation and function in response to high intensity interval exercise and moderate continuous exercise in CABG and PCI patients. Clin Hemorheol Microcirc. 2016;64:911-919.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe